Danielle Valletti, Assistant Editor

Hesperidin, a citrus-derived flavonoid, shows promise in improving cholesterol, blood pressure, and metabolic health, particularly at higher doses and longer durations.

The FDA suspended the biologics license for Ixchiq, the first approved chikungunya vaccine, after reports of serious adverse events and fatalities.

Researchers have identified suppression of the JNK pathway, particularly loss of MAP2K7, as a key driver of resistance to endocrine therapy plus CDK4/6 inhibitors in ER+ breast cancer.

Pharmacists play crucial roles in opioid use disorder treatment.

The action follows phase 3 trial data that demonstrated reduced phlebotomy dependence, improved hematocrit control, and eased symptoms.

The recombinant shingles vaccine not only reduces herpes zoster and herpes zoster ophthalmicus but is also associated with lower risks of hospitalization for stroke and myocardial infarction in adults aged 50 and older.

A new study found that the natural alkaloids mitragynine and 7-hydroxymitragynine from Mitragyna speciosa showed stable binding and favorable drug-likeness as potential HER2 inhibitors in breast cancer.

The ASTER 70s trial found that adjuvant chemotherapy provided no significant survival benefit, but caused substantial toxicity in older women with high-risk HR-positive, HER2-negative breast cancer.

Discover groundbreaking FDA approvals for shingles, diabetes, and OTC treatment for gut health, enhancing patient care and access to essential medications.

Palbociclib revolutionizes HR+/HER2- breast cancer treatment, enhancing outcomes with endocrine therapies and promising new combinations for better patient care.

Probiotic supplementation in VLBW preterm infants reduces antibiotic resistance and promotes beneficial gut bacteria, enhancing neonatal health outcomes.

Study reveals rituximab outperforms cladribine in managing RRMS, showing superior disease control and improved disability outcomes.

Plozasiran significantly reduces triglyceride levels and pancreatitis risk in FCS patients, offering hope for effective treatment options.

Researchers unveil a promising drug combination, arainosine and theobromine, that effectively targets influenza A M2 channels, outperforming existing treatments.

Revumenib shows promise in treating NPM1-mutant AML, expanding its role in precision oncology and offering hope for targeted leukemia therapies.

New findings highlight environmental impacts on weight management.

Aficamten offers new hope for HCM patients, showing significant clinical benefits and safety in recent trials, enhancing treatment options.

Pharmacists explore kratom's potential benefits and risks, emphasizing the need for education on its effects, safety, and patient guidance.

Vitamins D and K work together to enhance bone strength and cardiovascular health, ensuring optimal calcium regulation for overall wellness.

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses how Medicaid payment changes could impact rural hospitals and local pharmacies, noting the importance of pharmacists staying involved as the situation develops.

Natural compounds like Prunus armeniaca and bee venom enhance breast cancer treatment, boosting efficacy and reducing adverse effects.

New research confirms oseltamivir (Tamiflu; Roche) is safe for children, reducing flu-related neuropsychiatric risks and encouraging timely antiviral treatment.

Discover effective strategies for managing opioid-induced constipation, including the role of PAMORAs and pharmacist involvement in pain management.

The FDA intends to update opioid labels to highlight risks of addiction, overdose, and interactions, enhancing safety in pain management practices.

The FDA approves dordaviprone, the first systemic therapy for H3 K27M-mutant diffuse midline glioma, offering hope for patients with limited options.

The FDA targets 7-hydroxymitragynine, a potent kratom derivative, as a controlled substance due to its opioid-like effects and rising health risks.

BPA exposure accelerates ER+ breast cancer growth, impacting treatment efficacy and altering the pharmacist's role in therapy administration.

Ivermectin shows promise in reducing malaria cases, enhancing vector control, and highlighting pharmacists' vital roles in public health strategies.

Hormonal contraceptives present a nuanced risk-benefit profile, slightly increasing breast and cervical cancer risk while significantly reducing ovarian and endometrial cancer rates.